Vglycin
Peptide Power for a Balanced Sweet Life
Your Key to Glycemic Harmony
In order to better browse the web, it is recommended to use a computer to watch.
Peptide Power for a Balanced Sweet Life
Your Key to Glycemic Harmony
Discover how vglycin can revolutionize the treatment of Type 2 Diabetes.
Diabetes is a chronic non-communicable lifelong disease that threatens the health of people around the world. Type 2 diabetes (T2D) accounts for over 90% of the total diabetes patients. [1.] The main clinical manifestation of T2D characterizes by a dysfunctional fasting blood glucose that reaches 7.0 mmol/L or higher, and insulin resistance caused by hyperglycemia.
With 537 million people affected today and projections rising, Type 2 Diabetes poses a growing global challenge.
Long-term hyperglycemia will continue to harm the health of diabetic patients, bringing various complications, including retinopathy, kidney disease, neuropathy, macrovascular disease, cardiomyopathy, infection, metabolic dysfunction, etc.
P37, a legume-derived 37 - amino - acid polypeptide, resists GI protease degradation and has an oral hypoglycemic effect. In its family, vglycin has obvious hypoglycemic and pancreas - repairing effects, suitable for type 2 diabetes treatment as a new oral medicine.
Currently, vglycin can only be extracted from soybeans with problems like low yield, complex process, and waste of land resources. Thus, to enable more people to benefit from vglycin - related treatment in the future, we plan to construct a vglycin expression vector using the synthetic biology method to increase its expression level.
Our biomanufacturing system aims to make Vglycin accessible, and allow further Vaglicin-based treatment to be furthes explored.